|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NUDCD1 |
Gene summary for NUDCD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NUDCD1 | Gene ID | 84955 |
| Gene name | NudC domain containing 1 | |
| Gene Alias | CML66 | |
| Cytomap | 8q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q96RS6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84955 | NUDCD1 | HCC1_Meng | Human | Liver | HCC | 1.61e-76 | 1.79e-01 | 0.0246 |
| 84955 | NUDCD1 | HCC2_Meng | Human | Liver | HCC | 8.18e-15 | 3.01e-02 | 0.0107 |
| 84955 | NUDCD1 | HCC2 | Human | Liver | HCC | 1.16e-02 | 1.79e+00 | 0.5341 |
| 84955 | NUDCD1 | Pt13.b | Human | Liver | HCC | 1.37e-07 | 1.23e-01 | 0.0251 |
| 84955 | NUDCD1 | S014 | Human | Liver | HCC | 5.59e-41 | 1.25e+00 | 0.2254 |
| 84955 | NUDCD1 | S015 | Human | Liver | HCC | 1.14e-35 | 1.48e+00 | 0.2375 |
| 84955 | NUDCD1 | S016 | Human | Liver | HCC | 2.23e-39 | 1.21e+00 | 0.2243 |
| 84955 | NUDCD1 | S027 | Human | Liver | HCC | 2.14e-10 | 9.28e-01 | 0.2446 |
| 84955 | NUDCD1 | S028 | Human | Liver | HCC | 5.09e-21 | 1.04e+00 | 0.2503 |
| 84955 | NUDCD1 | S029 | Human | Liver | HCC | 4.71e-29 | 1.17e+00 | 0.2581 |
| 84955 | NUDCD1 | C04 | Human | Oral cavity | OSCC | 7.94e-14 | 6.08e-01 | 0.2633 |
| 84955 | NUDCD1 | C21 | Human | Oral cavity | OSCC | 9.13e-36 | 1.15e+00 | 0.2678 |
| 84955 | NUDCD1 | C30 | Human | Oral cavity | OSCC | 6.60e-25 | 1.18e+00 | 0.3055 |
| 84955 | NUDCD1 | C43 | Human | Oral cavity | OSCC | 2.37e-18 | 3.50e-01 | 0.1704 |
| 84955 | NUDCD1 | C46 | Human | Oral cavity | OSCC | 1.82e-10 | 2.73e-01 | 0.1673 |
| 84955 | NUDCD1 | C51 | Human | Oral cavity | OSCC | 2.32e-05 | 4.65e-01 | 0.2674 |
| 84955 | NUDCD1 | C06 | Human | Oral cavity | OSCC | 5.69e-04 | 6.04e-01 | 0.2699 |
| 84955 | NUDCD1 | C08 | Human | Oral cavity | OSCC | 8.64e-14 | 3.81e-01 | 0.1919 |
| 84955 | NUDCD1 | LP15 | Human | Oral cavity | LP | 1.96e-03 | 4.96e-01 | 0.2174 |
| 84955 | NUDCD1 | SYSMH2 | Human | Oral cavity | OSCC | 5.38e-19 | 4.73e-01 | 0.2326 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NUDCD1 | SNV | Missense_Mutation | c.1152N>C | p.Met384Ile | p.M384I | Q96RS6 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| NUDCD1 | SNV | Missense_Mutation | rs543121980 | c.850N>A | p.Glu284Lys | p.E284K | Q96RS6 | protein_coding | tolerated(0.49) | benign(0.346) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDCD1 | SNV | Missense_Mutation | c.1554N>A | p.Phe518Leu | p.F518L | Q96RS6 | protein_coding | deleterious(0.01) | possibly_damaging(0.76) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NUDCD1 | SNV | Missense_Mutation | c.1643N>G | p.Ala548Gly | p.A548G | Q96RS6 | protein_coding | deleterious(0.01) | benign(0.133) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| NUDCD1 | SNV | Missense_Mutation | c.571N>A | p.Glu191Lys | p.E191K | Q96RS6 | protein_coding | deleterious(0.03) | benign(0.217) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| NUDCD1 | deletion | Frame_Shift_Del | novel | c.1457delT | p.Leu486Ter | p.L486* | Q96RS6 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| NUDCD1 | SNV | Missense_Mutation | c.488N>A | p.Pro163His | p.P163H | Q96RS6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| NUDCD1 | SNV | Missense_Mutation | novel | c.589N>C | p.Ser197Arg | p.S197R | Q96RS6 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NUDCD1 | SNV | Missense_Mutation | novel | c.544N>G | p.Thr182Ala | p.T182A | Q96RS6 | protein_coding | tolerated(0.11) | benign(0) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| NUDCD1 | SNV | Missense_Mutation | novel | c.1746N>T | p.Glu582Asp | p.E582D | Q96RS6 | protein_coding | tolerated(0.48) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |